e-learning
resources
Barcelona 2010
Sunday, 19.09.2010
News from RCT (randomised controlled trials) and epidemiology in sleep apnoea
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effects of CPAP and valsartan randomly assigned on baroreflex function and aldosterone in hypertensive OSAS
R. Tamisier, D. Lacedonia, D. Monneret, J. P. Baguet, P. Levy, J. L. Pepin (La Tronche, Grenoble Cedex 09, France)
Source:
Annual Congress 2010 - News from RCT (randomised controlled trials) and epidemiology in sleep apnoea
Session:
News from RCT (randomised controlled trials) and epidemiology in sleep apnoea
Session type:
Oral Presentation
Number:
1663
Disease area:
Sleep and breathing disorders
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Tamisier, D. Lacedonia, D. Monneret, J. P. Baguet, P. Levy, J. L. Pepin (La Tronche, Grenoble Cedex 09, France). Effects of CPAP and valsartan randomly assigned on baroreflex function and aldosterone in hypertensive OSAS. Eur Respir J 2010; 36: Suppl. 54, 1663
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Clinical case discussion: ERS guidelines on high flow nasal cannula in acute respiratory failure: from the clinical cases to the scientific evidence
To code or not to code chronic pulmonary aspergillosis associated malnutrition in PMSI database: that is the problem…
Adherence predictors to positive airway pressure (PAP) treatment in patients with obstructive sleep apnea (OSA)
Related content which might interest you:
Impact of CPAP treatment on sympathetic activity and renin-angiotensin-aldosterone system in normotensive men with obstructive sleep apnoea
Source: Eur Respir J 2006; 28: Suppl. 50, 294s
Year: 2006
Comparison of continuous positive airway pressure and valsartan 160 mg in hypertensive sleep apnoea patients never treated for both conditions: the VALSAS study
Source: Annual Congress 2009 - Assessment and therapeutical interventions in obstructive sleep apnoea
Year: 2009
Long term effects of CPAP in blood pressure in nonsleepy hypertensive OSA patients
Source: Annual Congress 2008 - Clinical aspects of continuous positive airway pressure therapy
Year: 2008
No reduction of blood pressure with CPAP in non-sleepy hypertensive OSA patients
Source: ISSN=ISSN 1810-6838, ISBN=, page=193
Year: 2006
CPAP vs APAP effects on metabolic and cardiac function in patients with OSAS
Source: Eur Respir J 2005; 26: Suppl. 49, 722s
Year: 2005
Acetazolamide reduces blood pressure and sleep disordered breathing in hypertensive obstructive sleep apnoea patients – a randomized controlled trial
Source: International Congress 2017 – CPAP therapy
Year: 2017
Effects of autoCPAP treatment for obstructive sleep apnea on 24-hour blood pressure and nocturnal catecholamines
Source: Annual Congress 2009 - Continuous positive airway pressure therapy in obstructive sleep apnoea
Year: 2009
Sympathetic activity is reduced by nCPAP in hypertensive obstructive sleep apnoea patients
Source: Eur Respir J 2004; 23: 255-262
Year: 2004
CPAP and measures of cardiovascular risk in males with OSAS
Source: Eur Respir J 2008; 32: 1488-1496
Year: 2008
Ventilatory dysregulation and sleep apnea occurence in non-obese high-fat fed rats: effect of metformin treatment
Source: Eur Respir J 2004; 24: Suppl. 48, 333s
Year: 2004
Vagal and sympathetic component of arterial baroreflex are altered after 14 nights of intermittent hypoxia in healthy subjects
Source: Annual Congress 2008 - Pathogenesis of obstructive sleep apnoea
Year: 2008
Nocturnal melatonin plasma levels in patients with OSAS: the effect of CPAP
Source: Eur Respir J 2007; 30: 496-500
Year: 2007
Nocturnal BP pattern and cardiovascular risk in a group of patients with moderate-severe OSAS. Evaluation of the effect of CPAP treatment
Source: Eur Respir J 2007; 30: Suppl. 51, 335s
Year: 2007
Glucose metabolism markers in non-diabetic OSAS patients. Effect of compliance to CPAP treatment
Source: Annual Congress 2008 - Metabolic and sex-related aspects of obstructive sleep apnoea
Year: 2008
Cardiovascular and metabolic effects of CPAP in obese males with OSA
Source: Eur Respir J 2007; 29: 720-727
Year: 2007
Comparative effects of amlodipine and sildenafil on the NT-proBNP levels of patients with COPD-induced pulmonary hypertension
Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease
Year: 2011
Effect of continuous positive airway pressure on 24 h ambulatory blood pressure in hypertensive patients with OSA
Source: Eur Respir J 2007; 30: Suppl. 51, 333s
Year: 2007
14 nights of intermittent hypoxia elevate daytime blood pressure and sympathetic activity in healthy humans
Source: Eur Respir J 2011; 37: 119-128
Year: 2011
Role of plasmatic leptin in response to hypercapnia in obese patients with or without OSAS
Source: Annual Congress 2007 - Pathogenesis of obstructive sleep apnoea
Year: 2007
CPAP versus CPAP plus low dose of PDE-inhibitor in men with obstructive sleep apnea-hypopnea syndrome (OSAHS) and erectile dysfunction (ED)
Source: Annual Congress 2010 - Clinical aspects of sleep apnoea
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept